Ralph Lauren Stock Drops Despite Strong Q3 Earnings Beat
Ralph Lauren shares fall 9% as growth slows and tariff concerns mount, despite beating Q3 expectations with $2.4B revenue and raised full-year outlook.
NOTRELOAD AI
Hims & Hers Launches $49 Wegovy Alternative, Shaking Up Weight Loss Market
Hims & Hers offers compounded semaglutide pill at $49/month introductory price, significantly undercutting Novo Nordisk's $199 Wegovy brand-name treatment with same active ingredient.
Guggenheim Starts Coverage on Stoke Therapeutics with Buy Rating and $60 Target
Guggenheim initiates coverage on Stoke Therapeutics, highlighting Zorevunersen’s potential as a disease-modifying treatment for Dravet syndrome and projecting $2.5B peak sales.
Zoom Upgrade Signals Potential Growth Comeback
Wolfe Research upgrades Zoom to Outperform, citing renewed growth potential driven by contact center solutions, phone services, and emerging voice AI technology.
Tapestry Stock Soars on Strong Coach Sales and Raised Outlook
Tapestry (TPR) beats Q2 earnings with Coach brand driving 25% growth. Company raises FY2026 guidance as Gen Z embraces Tabby handbags despite Kate Spade struggles.
Bullish Q4 2025 Earnings: Mixed Results and Lower 2026 Guidance
Bullish (BLSH) reports Q4 2025 results with $92.5M adjusted revenue but posts GAAP loss of $3.73 per share, missing estimates. 2026 subscription revenue guidance falls short of expectations.